KI16425 Property

Melting point:

59.5-60.5 °C

Boiling point:

623.7±55.0 °C(Predicted)

Density 

1.353

storage temp. 

-20°C

solubility 

DMSO: 16 mg/mL

form 

solid

pka

4.32±0.10(Predicted)

color 

white

Safety

Hazard Codes 

Xi

Risk Statements 

36/37/38

Safety Statements 

26-36

WGK Germany 

3

HS Code 

29349990

Hazard and Precautionary Statements (GHS)

KI16425 Chemical Properties,Usage,Production

Description

Lysophosphatidic acid (LPA) is a bioactive lipid mediator that signals through five distinct G protein-coupled receptors (LPA_1-5). Ki16425 is a LPA receptor antagonist with selectivity for LPA₁ and LPA₃. It exhibits K_i values of 0.34, 6.5, and 0.93 μM for the human LPA₁, LPA₂, and LPA₃ receptors, respectively, as determined by measuring inositol phosphate production in RH7777-transfected cells. Ki1642, at 10 μM, significantly blocks the response of a variety of cancer cell lines to LPA-induced cell migration.

Uses

Ki 16425 has been used as a chemical inhibitor to study the regulation of LPA (lysophosphatidic acid) on LPAR(LPA receptor) subtypes.

Uses

Ki16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3.

Definition

ChEBI: 3-[({4-[4-({[1-(2-chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid is a member of the class of isoxazoles that is the carbamate ester obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)ethyl hydrogen carbonate with the amino group of 3-({[4-(4-amino-3-methyl-1,2-oxazol-5-yl)phenyl]methyl}sulfanyl)propanoic acid. It is a member of isoxazoles, a carbamate ester, a member of monochlorobenzenes, an organic sulfide and a monocarboxylic acid.

Biochem/physiol Actions

Ki 16425 possesses a short-lived inhibitory activity. It has been studied that Ki 16425 is effective in the inhibition of neuropathic pain‐like behaviors.

storage

Store at +4°C

References

[1]. ohta h, sato k, murata n, damirin a, malchinkhuu e, kon j, kimura t, tobo m, yamazaki y, watanabe t, yagi m, sato m, suzuki r, murooka h, sakai t, nishitoba t, im ds, nochi h, tamoto k, tomura h, okajima f. ki16425, a subtype-selective antagonist for edg-family lysophosphatidic acid receptors. mol pharmacol. 2003 oct;64(4):994-1005.
[2]. ruisanchez é, dancs p, kerék m, németh t, faragó b, balogh a, patil r, jennings bl, liliom k, malik ku, smrcka av, tigyi g, benyó z. lysophosphatidic acid induces vasodilation mediated by lpa1 receptors, phospholipase c, and endothelial nitric oxide synthase. faseb j. 2014 feb;28(2):880-90.
[3]. su sc, hu x, kenney pa, merrill mm, babaian kn, zhang xy, maity t, yang sf, lin x, wood cg. autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma. clin cancer res. 2013 dec 1;19(23):6461-72.
[4]. david m, sahay d, mege f, descotes f, leblanc r, ribeiro j, clézardin p, peyruchaud o. identification of heparin-binding egf-like growth factor (hb-egf) as a biomarker for lysophosphatidic acid receptor type 1 (lpa1) activation in human breast and prostate cancers. plos one. 2014 may 14;9(5):e97771.